Field Case Studies
At Equiceutica, our commitment to advancing patient care through scientifically backed, high-bioavailability liposomal formulations is at the heart of everything we do. This series of field case studies showcases real-world applications of our products by leading clinicians across diverse specialties. By partnering with top medical professionals, we are able to capture clinical insights, observe measurable outcomes, and highlight the innovative ways Equiceutica solutions are supporting optimized health and recovery in practice.
Patient: Capitu Species: Canine Breed:Great Dane Age: 10 Sex: Female (S) Weight: 51 kg
Capitu began showing signs of joint pain, lameness, and difficulty moving, particularly when trying to stand up. After a comprehensive general and orthopedic clinical examination, she was diagnosed with bilateral hip joint disease, with severe osteoarthritis, more pronounced on the right side. A pain and inflammation management protocol was initiated, consisting of firocoxib and dipyrone monohydrate. Fourteen days after the initial consultation, a follow-up evaluation was conducted, revealing only a limited response to the established protocol.
As a result, a treatment plan incorporating liposomal CBD was introduced. Capitu was initially administered 0.5 mg/kg twice daily for five days, followed by a maintenance dose of 0.3 mg/kg once daily for long-term management. Another follow-up was performed 14 days later, including a clinical examination and an owner questionnaire. The results indicated a 50% improvement in Capitu’s pain levels, with fewer pain-related signs and enhanced mobility. Although she had not yet returned to her previous level of comfort and mobility, she showed noticeable improvement, particularly in standing up and lying down, which she could now perform with greater ease."
Veterinarian: Dr Rodrigo Zamith Cunha, EquiCeutica Chief Scientific & Veterinary Officer
_edited.jpg)
Case Study: Luca a 12 year old Vizsla. Weight 20kgs. August 2021. EquiCeutica Cannabinoid treatment:
.webp)
Veterinarians had recommended euthanasia. Luca was given 3 ml of EquiCeutica CBD administered sublingually and within 48 hours had shown signs of recovery. Within 30 days he had recovered full fitness and weight of 28 kg. Luca retained appetite, condition and full mobility until his death in December 2022 aged 14 years 8 months with daily 2-3 ml EquiCeutica CBD with no adverse reaction. It was noted that response time was 10-15 minutes.
Veterinarian: Paula San Roman. Vet Polo Club de St Tropez
Patient: Kovu Species: Canine Breed: Great Dane Age: 4 Sex: Male (S) Weight: 69 kg
Kovu was diagnosed with an eosinophilic granuloma on the dorsal aspect of the right metatarsus, presenting as a chronic ulcerative wound. Diagnosis was made with cytology and histopathology. The owners reported significant difficulty in managing the condition, as Kovu persistently found ways to bite or chew at the affected area. No systemic clinical signs were observed, apart from pronounced behavioral changes caused by intense pruritus. Previous treatments included surgical removal with a skin graft, which was unsuccessful because the patient chewed it off, as well as local and systemic corticosteroids, which led to undesirable long-term side effects. Various wound management approaches were attempted, but each ultimately failed due to the patient biting the wound, despite the owners’ efforts to use an Elizabethan collar and a muzzle. As a result EquiCeutica Liposomal-Encapsulated CBD was administered at 0.3 mg/kg once daily, combined with topical silver sulfadiazine and EquiCeutica Liposomal-Encapsulated CBD under bandaging. Currently, the wound has fully closed, though hair regrowth is still in progress. The pruritus has been effectively controlled, which has contributed to improved wound healing. Additionally, this approach has significantly reduced costs for the owners, as fewer bandage changes have been required."
Veterinarian: Dr Rodrigo Zamith Cunha, EquiCeutica Chief Scientific & Veterinary Officer
After 20 days: